Can corticosteroids be beaten in future asthma therapy?

Area of Science:

• Pulmonology and Allergy
• Pharmacology

Background:

• Asthma morbidity and mortality are increasing despite therapeutic advances, indicating a need for novel treatments.
• Recent decades saw biological discoveries but limited new asthma drug development, with few exceptions like leukotriene receptor antagonists and monoclonal antibodies.
• Corticosteroids remain a cornerstone of asthma therapy due to their multifaceted actions, but safer alternatives are sought.

Purpose of the Study:

• To address the unmet need for improved asthma treatments.
• To explore the potential of enhancing existing corticosteroid therapies.
• To identify safer and effective therapeutic options for allergic disorders.

Main Methods:

• Review of recent advancements in asthma pharmacotherapy.
• Analysis of the limitations of current asthma treatments.
• Evaluation of novel corticosteroid derivatives and their therapeutic potential.

Main Results:

• Despite significant biological advancements, asthma therapy has seen minimal innovation in the last decade.
• Corticosteroids are still considered the most promising therapeutic agents, but their safety profile requires improvement.
• Soft-steroids, such as loteprednol and etiprednol, show promise as effective and safer treatments.

Conclusions:

• There is an urgent need for new and improved asthma treatments.
• Enhancing the safety and efficacy of corticosteroids is a key future direction.
• Soft-steroids represent a promising avenue for future asthma and allergic disorder management.